| Year |
Citation |
Score |
| 2021 |
Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, ... ... Cummings JL, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet. Neurology. PMID 33933186 DOI: 10.1016/S1474-4422(21)00066-1 |
0.328 |
|
| 2021 |
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, ... Cummings JL, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Research & Therapy. 13: 80. PMID 33865446 DOI: 10.1186/s13195-021-00813-8 |
0.307 |
|
| 2021 |
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet (London, England). PMID 33667416 DOI: 10.1016/S0140-6736(20)32205-4 |
0.328 |
|
| 2021 |
Liss JL, Seleri Marques Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, Devanand DP, Fillit HM, Susman J, Mintzer J, Bittner T, Brunton SA, Kerwin DR, Clay Jackson W, Small GW, et al. Practical Recommendations for Timely, Accurate Diagnosis of Symptomatic Alzheimer's Disease (MCI and Dementia) in Primary Care: A Review and Synthesis. Journal of Internal Medicine. PMID 33458891 DOI: 10.1111/joim.13244 |
0.304 |
|
| 2021 |
Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Molecular Neurodegeneration. 16: 2. PMID 33441154 DOI: 10.1186/s13024-021-00424-9 |
0.349 |
|
| 2020 |
Cummings J. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 32819825 DOI: 10.1016/J.Jagp.2020.07.011 |
0.309 |
|
| 2020 |
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimer's & Dementia (New York, N. Y.). 6: e12050. PMID 32695874 DOI: 10.1002/Trc2.12050 |
0.308 |
|
| 2020 |
Tariot P, Foff EP, Cummings JL, Soto-Martin M, McEvoy B, Stankovic S, Howard A. HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis Innovation in Aging. 4: 163-164. DOI: 10.1093/geroni/igaa057.530 |
0.327 |
|
| 2020 |
Foff EP, Cummings JL, Soto-Martin M, Tariot P, McEvoy B, Stankovic S. 427 - HARMONY study: pimavanserin significantly reduces risk of relapse of dementia-related psychosis International Psychogeriatrics. 32: 143-143. DOI: 10.1017/s104161022000280x |
0.329 |
|
| 2019 |
Fischer CE, Ismail Z, Youakim JM, Creese B, Kumar S, Nuñez N, Darby RR, Di Vita A, D'Antonio F, de Lena C, McGeown WJ, Ramit R, Rasmussen J, Bell J, Wang H, ... ... Cummings J, et al. Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. Journal of Alzheimer's Disease : Jad. PMID 31884469 DOI: 10.3233/Jad-190828 |
0.332 |
|
| 2019 |
Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Tariot PN, Raket LL. Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 164-174. PMID 31193334 DOI: 10.1016/J.Trci.2019.04.001 |
0.321 |
|
| 2019 |
Bayram E, Shan G, Cummings JL. Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 31127776 DOI: 10.3233/Jad-181285 |
0.309 |
|
| 2019 |
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. The New England Journal of Medicine. 380: 1408-1420. PMID 30970186 DOI: 10.1056/Nejmoa1812840 |
0.305 |
|
| 2019 |
Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 3: 138-144. PMID 29205252 DOI: 10.14283/jpad.2016.99 |
0.325 |
|
| 2018 |
Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Pimavanserin: Potential Treatment For Dementia-Related Psychosis. The Journal of Prevention of Alzheimer's Disease. 5: 253-258. PMID 30298184 DOI: 10.14283/jpad.2018.29 |
0.313 |
|
| 2018 |
Cummings J. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29936146 DOI: 10.1016/J.Jalz.2018.05.006 |
0.308 |
|
| 2018 |
Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Jama. 319: 130-142. PMID 29318278 DOI: 10.1001/Jama.2017.20373 |
0.336 |
|
| 2017 |
Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. The Journal of Prevention of Alzheimer's Disease. 4: 149-156. PMID 29182706 DOI: 10.14283/jpad.2017.26 |
0.317 |
|
| 2017 |
Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research & Therapy. 9: 60. PMID 28793924 DOI: 10.1186/S13195-017-0283-5 |
0.313 |
|
| 2017 |
Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, Freund-Levi Y. Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's Disease : Jad. PMID 28269767 DOI: 10.3233/Jad-160758 |
0.312 |
|
| 2016 |
Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 27010616 DOI: 10.1136/Jnnp-2015-312383 |
0.318 |
|
| 2016 |
Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, Dash A. Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. Cns Neuroscience & Therapeutics. PMID 26778658 DOI: 10.1111/Cns.12484 |
0.304 |
|
| 2015 |
Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). The Journal of Prevention of Alzheimer's Disease. 2: 227-241. PMID 27019841 DOI: 10.14283/jpad.2015.82 |
0.304 |
|
| 2015 |
Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research. 12: 712-22. PMID 26412218 DOI: 10.2174/1567205012666150701103107 |
0.325 |
|
| 2015 |
Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama. 314: 1242-54. PMID 26393847 DOI: 10.1001/Jama.2015.10214 |
0.33 |
|
| 2015 |
Cummings J, Zhong K. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. Clinical Pharmacology and Therapeutics. 98: 483-5. PMID 26206713 DOI: 10.1002/Cpt.190 |
0.318 |
|
| 2015 |
Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimer's Research & Therapy. 7: 43. PMID 26120369 DOI: 10.1186/S13195-015-0127-0 |
0.326 |
|
| 2015 |
Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer's disease: what, when, and why? Annals of Clinical and Translational Neurology. 2: 307-23. PMID 25815358 DOI: 10.1002/Acn3.166 |
0.332 |
|
| 2014 |
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, et al. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. The Journal of Prevention of Alzheimer's Disease. 1: 110-116. PMID 29255837 DOI: 10.14283/jpad.2014.6 |
0.303 |
|
| 2014 |
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, et al. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. The Journal of Prevention of Alzheimer's Disease. 1: 181-202. PMID 26478889 DOI: 10.14283/jpad.2014.32 |
0.304 |
|
| 2014 |
Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL. Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 38: 224-33. PMID 24903099 DOI: 10.1159/000362715 |
0.327 |
|
| 2014 |
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... ... Cummings JL, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0 |
0.314 |
|
| 2014 |
Cummings JL, Ringman J, Vinters HV. Neuropathologic correlates of trial-related instruments for Alzheimer's disease. American Journal of Neurodegenerative Disease. 3: 45-9. PMID 24754002 |
0.315 |
|
| 2014 |
Apostolova LG, Di LJ, Duffy EL, Brook J, Elashoff D, Tseng CH, Fairbanks L, Cummings JL. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 37: 315-26. PMID 24481207 DOI: 10.1159/000351009 |
0.319 |
|
| 2013 |
Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, Willis B, Cummings JL. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 607-22. PMID 23602309 DOI: 10.1016/J.Jagp.2012.10.027 |
0.326 |
|
| 2013 |
Dubois B, Gauthier S, Cummings J. The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics / Ipa. 25: 175-7. PMID 23148941 DOI: 10.1017/S1041610212002098 |
0.322 |
|
| 2013 |
Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiology of Aging. 34: 62-72. PMID 22503160 DOI: 10.1016/J.Neurobiolaging.2012.03.006 |
0.306 |
|
| 2012 |
Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Archives of Neurology. 69: 901-5. PMID 22431834 DOI: 10.1001/Archneurol.2011.3758 |
0.305 |
|
| 2012 |
Doody RS, Cummings JL, Farlow MR. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Current Alzheimer Research. 9: 773-81. PMID 22175653 DOI: 10.2174/156720512802455412 |
0.331 |
|
| 2011 |
Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. Bmc Neurology. 11: 21. PMID 21299848 DOI: 10.1186/1471-2377-11-21 |
0.315 |
|
| 2011 |
Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. International Journal of Geriatric Psychiatry. 26: 150-7. PMID 20597141 DOI: 10.1002/Gps.2507 |
0.305 |
|
| 2010 |
Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 431-9. PMID 21044773 DOI: 10.1016/J.Jalz.2010.04.003 |
0.316 |
|
| 2010 |
Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, et al. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet. Neurology. 9: 1118-27. PMID 20934914 DOI: 10.1016/S1474-4422(10)70223-4 |
0.319 |
|
| 2010 |
Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R, Schindler R, Schwam E. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. International Psychogeriatrics / Ipa. 22: 973-83. PMID 20534179 DOI: 10.1017/S1041610210000888 |
0.312 |
|
| 2010 |
Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders. 29: 406-12. PMID 20502014 DOI: 10.1159/000296073 |
0.305 |
|
| 2010 |
Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiology of Aging. 31: 1481-92. PMID 20447734 DOI: 10.1016/J.Neurobiolaging.2010.03.016 |
0.302 |
|
| 2010 |
Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. Journal of Alzheimer's Disease : Jad. 20: 301-11. PMID 20164585 DOI: 10.3233/Jad-2010-1362 |
0.338 |
|
| 2010 |
Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S. Evaluation of dementia rating scales in Parkinson's disease dementia. American Journal of Alzheimer's Disease and Other Dementias. 25: 142-8. PMID 19359706 DOI: 10.1177/1533317509333904 |
0.321 |
|
| 2009 |
Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings J, Xu Y, Feldman HH. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 28: 244-51. PMID 19786776 DOI: 10.1159/000241877 |
0.335 |
|
| 2008 |
Cummings JL. Controversies in Alzheimer's disease drug development. International Review of Psychiatry (Abingdon, England). 20: 389-95. PMID 18925488 DOI: 10.1080/09540260802094548 |
0.308 |
|
| 2008 |
Farlow MR, Cummings J. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 25: 301-8. PMID 18311077 DOI: 10.1159/000119104 |
0.329 |
|
| 2008 |
Cummings JL, Miller BL, Christensen DD, Cherry D. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease. Cns Spectrums. 13: 1-20; quiz 22. PMID 18264030 |
0.328 |
|
| 2008 |
Cummings JL. Update on Alzheimer's disease: One hundred years after Dr. Alois Alzheimer Primary Psychiatry. 15: 4-6. DOI: 10.1017/S1092852900002819 |
0.304 |
|
| 2007 |
Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Archives of Neurology. 64: 1489-95. PMID 17923632 DOI: 10.1001/Archneur.64.10.1489 |
0.321 |
|
| 2007 |
Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 24: 253-9. PMID 17700021 DOI: 10.1159/000107100 |
0.334 |
|
| 2007 |
Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. Journal of Alzheimer's Disease : Jad. 11: 509-19. PMID 17656830 DOI: 10.3233/Jad-2007-11412 |
0.345 |
|
| 2007 |
Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet. Neurology. 6: 501-12. PMID 17509485 DOI: 10.1016/S1474-4422(07)70109-6 |
0.312 |
|
| 2007 |
Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. The American Journal of Medicine. 120: 388-97. PMID 17466645 DOI: 10.1016/J.Amjmed.2006.08.036 |
0.309 |
|
| 2006 |
Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Disease and Associated Disorders. 20: 232-41. PMID 17132967 DOI: 10.1097/01.Wad.0000213862.20108.F5 |
0.311 |
|
| 2006 |
Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behavioural Neurology. 17: 5-16. PMID 16720956 DOI: 10.1155/2006/315386 |
0.35 |
|
| 2005 |
Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer's disease. Cns Spectrums. 10: 22-5. PMID 16273027 DOI: 10.1017/S1092852900014206 |
0.305 |
|
| 2005 |
Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. The American Journal of Geriatric Pharmacotherapy. 3: 137-48. PMID 16257816 DOI: 10.1016/S1543-5946(05)80020-0 |
0.333 |
|
| 2005 |
Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. Journal of Neurology, Neurosurgery, and Psychiatry. 76: 1337-41. PMID 16170072 DOI: 10.1136/jnnp.2004.056408 |
0.328 |
|
| 2005 |
Cummings JL. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease Neurology. 65: S18-S24. DOI: 10.1212/Wnl.65.6_Suppl_3.S18 |
0.345 |
|
| 2004 |
Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer disease. Archives of Neurology. 61: 556-60. PMID 15096405 DOI: 10.1001/Archneur.61.4.556 |
0.332 |
|
| 2004 |
Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 17: 100-8. PMID 14564129 DOI: 10.1159/000074281 |
0.306 |
|
| 2004 |
Senanarong V, Cummings JL, Fairbanks L, Mega M, Masterman DM, O'Connor SM, Strickland TL. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dementia and Geriatric Cognitive Disorders. 17: 14-20. PMID 14560060 DOI: 10.1159/000074080 |
0.361 |
|
| 2003 |
Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S, Cummings JL. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. The Journal of Neuropsychiatry and Clinical Neurosciences. 15: 180-6. PMID 12724459 DOI: 10.1176/Jnp.15.2.180 |
0.312 |
|
| 2002 |
Back-Madruga C, Boone KB, Briere J, Cummings J, McPherson S, Fairbanks L, Thompson E. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. The Clinical Neuropsychologist. 16: 331-40. PMID 12607146 DOI: 10.1076/Clin.16.3.331.13846 |
0.326 |
|
| 2001 |
Cummings JL, McPherson S. Neuropsychiatric assessment of Alzheimer's disease and related dementias. Aging (Milan, Italy). 13: 240-6. PMID 11444257 DOI: 10.1007/Bf03351482 |
0.314 |
|
| 2001 |
Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. International Psychogeriatrics / Ipa. 13: 121-8. PMID 11352329 DOI: 10.1017/S1041610201007517 |
0.314 |
|
| 2001 |
Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: 184-91. PMID 11241724 DOI: 10.1002/1099-1166(200102)16:2<184::Aid-Gps304>3.0.Co;2-K |
0.332 |
|
| 2000 |
Cummings JL. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 3: 21-29. PMID 11343621 DOI: 10.1017/S1461145700001917 |
0.303 |
|
| 2000 |
Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiology of Aging. 21: 845-61. PMID 11124429 DOI: 10.1016/S0197-4580(00)00183-4 |
0.311 |
|
| 2000 |
Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology. 54: 1616-25. PMID 10762503 DOI: 10.1212/Wnl.54.8.1616 |
0.323 |
|
| 1999 |
Ringman JM, Cummings JL. Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Expert Opinion On Investigational Drugs. 8: 463-71. PMID 15992092 DOI: 10.1517/13543784.8.4.463 |
0.326 |
|
| 1999 |
Cummings JL, Fairbanks L, Masterman DL. Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 2: 59-66. PMID 11281971 DOI: 10.1017/S1461145799001340 |
0.318 |
|
| 1999 |
Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC. The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Disease and Associated Disorders. 13: S21-9. PMID 10609678 DOI: 10.1097/00002093-199912001-00005 |
0.302 |
|
| 1999 |
Ringman JM, Cummings JL. Metrifonate: update on a new antidementia agent. The Journal of Clinical Psychiatry. 60: 776-82. PMID 10584768 DOI: 10.4088/Jcp.V60N1111 |
0.301 |
|
| 1999 |
Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, Vinters HV. Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Archives of Neurology. 56: 1254-61. PMID 10520942 DOI: 10.1001/Archneur.56.10.1254 |
0.304 |
|
| 1999 |
Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biological Psychiatry. 45: 422-5. PMID 10071711 DOI: 10.1016/S0006-3223(98)00041-9 |
0.321 |
|
| 1999 |
Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology. 15-22. PMID 9876214 DOI: 10.1159/000052760 |
0.325 |
|
| 1998 |
Mendez MF, Perryman KM, Miller BL, Cummings JL. Behavioral differences between frontotemporal dementia and Alzheimer's disease: a comparison on the BEHAVE-AD rating scale. International Psychogeriatrics. 10: 155-62. PMID 9677502 DOI: 10.1017/S1041610298005262 |
0.332 |
|
| 1997 |
Mendez MF, Perryman KM, Miller BL, Swartz JR, Cummings JL. Compulsive behaviors as presenting symptoms of frontotemporal dementia. Journal of Geriatric Psychiatry and Neurology. 10: 154-7. PMID 9453681 DOI: 10.1177/089198879701000405 |
0.326 |
|
| 1997 |
Masterman DL, Mendez MF, Fairbanks LA, Cummings JL. Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. Journal of Geriatric Psychiatry and Neurology. 10: 15-21. PMID 9100154 DOI: 10.1177/089198879701000104 |
0.301 |
|
| 1996 |
Mendez MF, Cherrier M, Perryman KM, Pachana N, Miller BL, Cummings JL. Frontotemporal dementia versus Alzheimer's disease: differential cognitive features. Neurology. 47: 1189-94. PMID 8909428 DOI: 10.1212/Wnl.47.5.1189 |
0.335 |
|
| 1996 |
Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 47: 876-83. PMID 8857712 DOI: 10.1212/Wnl.47.4.876 |
0.3 |
|
| 1993 |
Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biological Psychiatry. 33: 536-41. PMID 8513039 DOI: 10.1016/0006-3223(93)90009-3 |
0.323 |
|
| 1993 |
Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. The American Journal of Psychiatry. 150: 1806-12. PMID 8238634 DOI: 10.1176/Ajp.150.12.1806 |
0.305 |
|
| 1992 |
Flynn FG, Cummings JL, Gornbein J. Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. The Journal of Neuropsychiatry and Clinical Neurosciences. 3: 364-70. PMID 1821254 DOI: 10.1176/JNP.3.4.364 |
0.302 |
|
| 1992 |
Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. Journal of the American Geriatrics Society. 40: 549-55. PMID 1587970 DOI: 10.1111/J.1532-5415.1992.Tb02101.X |
0.324 |
|
| 1987 |
Cummings JL. Probable Alzheimer's Disease in an Artist Jama: the Journal of the American Medical Association. 258: 2731. DOI: 10.1001/Jama.1987.03400190113039 |
0.32 |
|
| 1984 |
Cummings JL, Benson DF. Subcortical dementia. Review of an emerging concept. Archives of Neurology. 41: 874-9. PMID 6235797 DOI: 10.1001/Archneur.1984.04050190080019 |
0.323 |
|
| Show low-probability matches. |